Medscape

Fingolimod May Not Be Publicly Funded in UK

August 5, 2011 — Fingolimod (Gilenya, Novartis), the new oral agent for relapsing–remitting multiple sclerosis, might not be publicly funded in the United Kingdom. In a report released today, the ...
Medscape

FDA Advisory Committee Endorses Fingolimod for Relapsing-Remitting Multiple Sclerosis

June 11, 2010 — The US Food and Drug Administration's (FDA's) Peripheral and Central Nervous System Drugs Advisory Committee has recommended approval for the novel oral agent fingolimod in the ...
News Medical

Real risk of rebound syndrome following fingolimod cessation for MS

Rebound syndrome following cessation of fingolimod for multiple sclerosis (MS) occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and ...
News Medical

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya ® (fingolimod) vs. interferon beta-1a, in children and adolescents ...
Insider Monkey

Novartis AG (NVS) To Present New Data on Kesimpta at ECTRIMS 2025 in Barcelona

Novartis AG (NYSE:NVS) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 24, Novartis AG (NYSE:NVS) announced that new data on Kesimpta for relapsing multiple ...